09 Dec Amphivena Presents Preclinical Data at ASH that Points to a Potentially New Treatment for MDS Patients
SOUTH SAN FRANCISCO --December 9, 2017 --AmphivenaTherapeutics Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell redirector for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), will present today in an oral presentation at the 59thAnnual Meeting of the...